Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia (PREVENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03373435
Recruitment Status : Completed
First Posted : December 14, 2017
Last Update Posted : February 11, 2019
Sponsor:
Information provided by (Responsible Party):
Eiger BioPharmaceuticals

Brief Summary:
This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).

Condition or disease Intervention/treatment Phase
Postbariatric Hypoglycemia Drug: exendin 9-39 Other: Placebo Phase 2

Detailed Description:

This is a Phase 2, multicenter, randomized, single-blind, placebo-controlled cross-over study in patients with refractory PBH.

Participants will be randomized and assigned in a 1:1 ratio to one of two treatment arms. All participants will receive 2 dosing regimens of exendin 9-39 and matching placebo self-administered via subcutaneous (SC) injection.

Participants will undergo in-clinic mixed meal tolerance test (MMTT) provocation with concomitant blood draws and symptom assessments.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
Actual Study Start Date : March 19, 2018
Actual Primary Completion Date : September 19, 2018
Actual Study Completion Date : October 15, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypoglycemia
Drug Information available for: Glucagon

Arm Intervention/treatment
Experimental: Treatment Group 1
patients will receive two dose regimens of exendin 9-39 and one placebo
Drug: exendin 9-39
Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
Other Name: Glucagon-like peptide-1 (GLP-1) antagonist

Other: Placebo
Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.

Experimental: Treatment Group 2
patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)
Drug: exendin 9-39
Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
Other Name: Glucagon-like peptide-1 (GLP-1) antagonist

Other: Placebo
Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.




Primary Outcome Measures :
  1. Postprandial Hypoglycemia [ Time Frame: 3 hours following a liquid meal ]
    Plasma glucose nadir occurring within 3 hours of MMTT

  2. Incidence of treatment-emergent adverse events [ Time Frame: 6 weeks ]
    An adverse event can be any unfavorable and unintended sign, symptom, or disease that occurs during the study treatment periods.


Secondary Outcome Measures :
  1. Severity score of postprandial neuroglycopenic signs and symptoms calculated from patients' responses to the Edinburgh Hypoglycemia Symptom Scale. (EHSS). [ Time Frame: 3 hours following a liquid meal ]
    Neuroglycopenic symptoms evaluated by the EHSS include blurred vision, confusion, drowsiness, speech difficulty, incoordination, dizziness, and inability to concentrate. Patients will complete the EHSS approximately every 30 minutes during each MMTT.

  2. Postprandial hyperinsulinemia. [ Time Frame: 3 hours following a liquid meal ]
    Peak postprandial insulin concentration in response to MMTT



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body mass index (BMI) of up to 40 kg/m2
  • Roux-en-Y gastric bypass (RYGB) surgery performed ≥12 months prior
  • Diagnosis of PBH
  • At least 2 episodes during screening 2-week run-in phase of severe hypoglycemia

Exclusion Criteria:

  • Other cause of endogenous hyperinsulinism other than PBH
  • Metabolic or bariatric surgical procedure other than RYGB
  • History of non-RYGB upper GI surgery
  • Use of agents that may interfere with glucose metabolism

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03373435


Locations
Layout table for location information
United States, California
Stanford University
Palo Alto, California, United States, 94304
United States, Colorado
University of Colorado, Denver
Aurora, Colorado, United States, 80045
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, North Carolina
Duke Early Phase Clinical Research
Durham, North Carolina, United States, 27710
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Eiger BioPharmaceuticals
Investigators
Layout table for investigator information
Study Director: Colleen Craig, MD Eiger BioPharmaceuticals, Inc

Layout table for additonal information
Responsible Party: Eiger BioPharmaceuticals
ClinicalTrials.gov Identifier: NCT03373435     History of Changes
Other Study ID Numbers: EIG-EXD-001
First Posted: December 14, 2017    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypoglycemia
Glucose Metabolism Disorders
Metabolic Diseases
Glucagon-Like Peptide 1
Glucagon
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Gastrointestinal Agents